MetaVia Reports 9.1% Weight Loss at 48 mg DA-1726 and 23.6% Reduction with Vanoglipel-Resmetirom
MTVA•MetaVia reported Phase 1 DA-1726 48 mg cohort delivered 9.1% weight loss and 9.8 cm waist reduction at Day 54 with favorable safety, supporting dose escalation. Preclinical vanoglipel combos achieved 23.6% weight loss with resmetirom and 16.3% weight loss plus 28.7% non-fasting glucose reduction with metformin, underscoring potential MASH and T2D combination therapies.
1. DA-1726 Phase 1 Higher-Dose Cohort Achieves Clinically Meaningful Weight Reduction
MetaVia’s randomized, placebo-controlled Phase 1 multiple ascending dose study in obese adults showed the 48 mg DA-1726 cohort achieved 6.1% mean body weight reduction at Day 26 and 9.1% at Day 54, with waist circumference down 9.8 cm and BMI reduced by 3.4 kg/m². The regimen was generally well tolerated, with mild-to-moderate gastrointestinal events and no serious adverse events or discontinuations.
2. Vanoglipel and Resmetirom Combination in MASH Model
MetaVia’s preclinical MASH study in diet-induced obese mice demonstrated that vanoglipel combined with resmetirom yielded 23.6% body weight reduction versus control, 43.5% fat mass reduction and 42.1% epididymal fat decrease, alongside an 83.5% ALT reduction and significant improvements in hepatic lipid accumulation, inflammation and fibrosis biomarkers.
3. Vanoglipel and Metformin Combination in T2D Model
MetaVia’s preclinical T2D study in diet-induced obese mice found vanoglipel plus metformin reduced non-fasting glucose by 28.7% and fasting glucose by 22.7% versus control, while driving a 16.3% body weight reduction and 25.6% fat mass decrease. These effects were accompanied by 6.4-fold GLP-1 and 1.5-fold PYY increases and reduced food intake.
4. Pipeline Advancement and Next Steps
The Phase 1 DA-1726 safety and dose-proportional pharmacokinetics support higher-dose evaluation in Part 3 titration studies, with results expected in Q4 2026, while vanoglipel’s synergistic benefits with resmetirom and metformin validate its potential as a combination backbone for MASH and type 2 diabetes therapies.
